Glenmark Pharmaceuticals Limited (GLENMARK) — Announcement | 7 August 2026

· NSE Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings
📢 Key Event
Glenmark schedules investor meetings with analysts and institutions
💡 Investor Takeaway
Investors should monitor these meetings for potential strategic updates or market sentiment shifts.

Glenmark Pharmaceuticals announced its schedule of analyst and institutional investor meetings in August and September 2026, including sessions with Emkay, Motilal Oswal, Elara India, and Kotak. The company emphasized no UPSI will be shared during these physical meetings, which are subject to change. These events signal proactive engagement with investors ahead of potential strategic updates, though no financial results or guidance were disclosed.

📄 View Original Announcement (PDF)

About Glenmark Pharmaceuticals Limited (GLENMARK)

Healthcare · Pharmaceuticals · Listed on NSE

Market Cap: ₹68,205.11 Cr P/E: 37.9 ROE: 20.3% ROCE: 24.8% Div Yield: 0.10%

View full GLENMARK stock details →

📡 Get AI alerts when GLENMARK files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track GLENMARK — Free

📊 More GLENMARK filings

See all GLENMARK filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when GLENMARK files new disclosures

Track GLENMARK filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track GLENMARK — Free

Free account · 2 AI queries/day